Medtronic plc
Moat Score — Medtronic plc
Total Moat Score
16 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Patent protection on implantable devices and lengthy FDA/international regulatory approval pathways create substantial, multi-year barriers to entry, reinforced by a trusted clinical brand built on outcomes data across more than 30 disease areas. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | Scale in R&D and global manufacturing lets Medtronic fund a broader therapy pipeline than most rivals, but it is not fundamentally a low-cost producer, and hospital/GPO purchasing power limits how much of that scale translates into margin advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Hospital systems and group purchasing organizations exert real downward pressure on device pricing, and reimbursement policy from government and private payers further constrains Medtronic's ability to raise prices freely. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Medical devices are sold and used individually per patient/procedure with no network dynamic where added users increase value to existing users. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Physicians are conservative about switching device platforms once trained and comfortable with clinical outcomes, and implantable devices in particular create long-lived, sticky relationships that are costly and risky to disrupt. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The capital and regulatory cost of developing competitive device platforms limits most therapeutic areas to a handful of large players, though Medtronic has visibly lost share to more focused competitors (Dexcom, Insulet, Intuitive Surgical) in diabetes and robotics, showing the barrier isn't absolute. |